Liquidia Corporation (LQDA)
| Market Cap | 4.03B +108.7% |
| Revenue (ttm) | 450.91M +2,233.6% |
| Net Income | 138.61M |
| EPS | 1.48 |
| Shares Out | 89.51M |
| PE Ratio | 30.49 |
| Forward PE | 42.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,091,716 |
| Open | 44.56 |
| Previous Close | 44.99 |
| Day's Range | 44.24 - 46.29 |
| 52-Week Range | 22.21 - 93.61 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 54.38 (+20.68%) |
| Est. Earnings | Nov 13, 2026 |
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L6... [Read more]
Financial Performance
In 2025, Liquidia's revenue was $158.32 million, an increase of 1031.18% compared to the previous year's $14.00 million. Losses were -$68.92 million, -46.28% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for LQDA stock is "Buy." The 12-month stock price target is $54.38, which is an increase of 20.68% from the latest price.
News
Liquidia price target raised to $42 from $38 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Liquidia (LQDA) to $42 from $38 and keeps a Neutral rating on the shares following a global litigation settlement with…
Liquidia price target raised to $65 from $58 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Liquidia (LQDA) to $65 from $58 and keeps a Buy rating on the shares after the company announced a global settlement with…
This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.
Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.
LifeSci upgrades Liquidia to Buy on overhang clearing settlement
LifeSci Capital upgraded Liquidia (LQDA) to Outperform from Market Perform with a $59 price target. The company announced a settlement with United Therapeutics (UTHR) that resolves all six pending law...
Liquidia upgraded to Outperform from Market Perform at LifeSci Capital
LifeSci Capital analyst Gaurav Maini upgraded Liquidia (LQDA) to Outperform from Market Perform with a $59 price target
Liquidia price target lowered to $58 from $72 at Needham
Needham lowered the firm’s price target on Liquidia (LQDA) to $58 from $72 and keeps a Buy rating on the shares. The firm is adjusting its model after the company…
Liquidia price target raised to $33 from $30 at Wells Fargo
Wells Fargo raised the firm’s price target on Liquidia (LQDA) to $33 from $30 and keeps an Equal Weight rating on the shares after the company and United Therapeutics (UTHR)…
Liquidia upgraded at BTIG after ‘much more favorable’ than expected settlement
As previously reported, BTIG upgraded Liquidia (LQDA) to Buy from Neutral with a $70 price target after the company announced it reached a global settlement with United Therapeutics (UTHR) to…
Liquidia upgraded to Buy from Neutral at BTIG
BTIG upgraded Liquidia (LQDA) to Buy from Neutral with a $70 price target
Liquidia Stock (LQDA) Pops as $380.7M Deal Ends Legal Battle with United Therapeutics
Liquidia ($LQDA) stock jumped about 47% in Wednesday’s pre-market trading after the biopharmaceutical company focused on respiratory and vascular diseases announced a $380.7 million settlement with Un...
Closing Bell Movers: Liquidia jumps on settlement with United Therapeutics
The yield on the 10-year Treasury note slipped below 5.2% for the first time in nearly two weeks on Tuesday, and yet sentiment in equities remained cautious, with little support…
Liquidia to pay $175M UTHR after settlement agreement
Liquidia (LQDA) and United Therapeutics (UTHR) reached a global settlement agreement that resolves all pending litigation between the companies. YUTREPIA, or treprostinil, inhalation powder will remai...
Liquidia up 40% to $37.59 after settlement agreement with United Therapeutics
17:57 EDT Liquidia (LQDA) up 40% to $37.59 after settlement agreement with United Therapeutics (UTHR)
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challengi...
LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $LQDA--LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law.
LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation
A court finding that Yutrepia infringed two valid claims of United Therapeutics' '327 patent has put the drug's PH-ILD indication and broader availability at risk. SueWallSt notifies investors of a pe...
Liquidia slumps after US court rules for United Therapeutics in patent fight
Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by rival United Therapeutics , dealing a major blow to the treatment's commer...
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
District Court ruled that two of the six claims asserted against Liquidia are valid and infringed Parties directed to submit form of judgment, specifying the proposed remedy, for the District Court's ...
Liquidia Transcript: Wells Fargo 21st Annual Healthcare Conference
YUTREPIA's launch has driven rapid revenue and patient growth, with strong adoption among naive patients and switches. The pipeline includes multiple late-stage trials, notably for L606, and expansion into new indications like PH-COPD and Raynaud's. Financial performance is robust, with a focus on sustained profitability and strategic reinvestment.
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
Fast Track designation underscores the significant unmet need for patients with systemic sclerosis-associated Raynaud's phenomenon (SSc-RP), a debilitating manifestation affecting up to 90% of SSc pat...
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challeng...
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
MORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chi...
Liquidia Earnings Call Transcript: Q2 2026
YUTREPIA's rapid adoption drove 31% QoQ sales growth and nearly 30% market share in the inhaled prostacyclin segment, with strong profitability and cash flow supporting expanded R&D and commercial investments. The company remains confident in surpassing $1 billion in net revenue by 2027.